Valuation: AstraZeneca PLC

Market Cap 245B 212B 199B 182B 342B 23,392B 347B 2,345B 915B 11,710B 920B 900B 39,062B P/E 2026 *
20.2x
P/E 2027 * 17.6x
Enterprise Value 264B 229B 215B 196B 369B 25,237B 375B 2,530B 988B 12,633B 993B 971B 42,142B EV / Sales 2026 *
4.18x
EV / Sales 2027 * 3.84x
Free-Float
96.63%
Yield 2026 *
2.1%
Yield 2027 * 2.23%
1 day-0.93%
Current month+69.49%
Current year+71.04%
Current year 89.04
Extreme 89.04
158.44
1 year 72.9
Extreme 72.895
158.44
3 years 60.47
Extreme 60.47
158.44
5 years 52.65
Extreme 52.65
158.44
10 years 25.55
Extreme 25.55
158.44
Manager TitleAgeSince
Chief Executive Officer 66 30/09/2012
Director of Finance/CFO 52 31/07/2021
Compliance Officer - 31/12/2022
Director TitleAgeSince
Director/Board Member 70 05/04/1999
Director/Board Member 66 30/09/2012
Director/Board Member 65 26/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.79%-2.38% - - 245B
-0.92%+1.43%+83.05%+128.86% 1,078B
+0.47%+1.98%+50.26%+50.75% 632B
+0.83%+2.85%+24.49%+64.82% 443B
-1.92%-3.19%+42.18%+34.26% 356B
-1.76%-3.38%+23.49%+33.88% 289B
-1.73%-3.23%-0.64%+3.58% 245B
+0.40%+3.21%+44.42%+59.17% 226B
+0.64%-1.87%-7.73%-51.66% 204B
+1.67%+5.56%+14.98%+72.68% 171B
Average -0.59%+1.43%+30.50%+44.04% 404.85B
Weighted average by Cap. -0.60%+1.30%+45.22%+65.27%

Financials

2026 *2027 *
Net sales 63.25B 54.83B 51.4B 46.86B 88.18B 6,037B 89.59B 605B 236B 3,022B 237B 232B 10,080B 66.85B 57.95B 54.32B 49.53B 93.2B 6,381B 94.69B 640B 250B 3,194B 251B 246B 10,655B
Net income 12.07B 10.46B 9.81B 8.94B 16.83B 1,152B 17.1B 115B 45.08B 577B 45.31B 44.33B 1,924B 13.72B 11.89B 11.14B 10.16B 19.12B 1,309B 19.43B 131B 51.23B 655B 51.49B 50.38B 2,186B
Net Debt 19.33B 16.75B 15.7B 14.32B 26.94B 1,844B 27.37B 185B 72.19B 923B 72.56B 70.98B 3,080B 11.66B 10.11B 9.47B 8.64B 16.25B 1,113B 16.51B 112B 43.55B 557B 43.77B 42.82B 1,858B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
14/08/26 US$155.79 -0.92% 652,310
13/08/26 US$157.24 -0.79% 3,598,337
12/08/26 US$158.50 -0.16% 4,140,379
11/08/26 US$158.75 -1.95% 2,754,805
10/08/26 US$161.91 +0.30% 3,745,982
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
158.02USD
Average target price
211.68USD
Spread / Average Target
+33.95%

Quarterly revenue - Rate of surprise